A clinical trial is currently recruiting patients to assess the effectiveness of Olorinab to treat abdominal pain associated with irritable bowel syndrome.
Irritable bowel syndrome (IBS), is a gastrointestinal disorder that is frequently associated with cramping, bloating, abdominal pain, constipation, diarrhea, and gas. There is no cure for IBS and patients manage symptoms typically with combinations of lifestyle and dietary changes, and medication.
Olorinab, a cannabinoid type 2 receptor agonist
Olorinab is an oral medication that is currently being tested for treatment of pain associated with gastrointestinal disorders, such as IBS. The drug acts on the type 2 cannabinoid receptor, but not the type 1 cannabinoid receptor, which means it is able to relieve pain but not induce any psychoactive effects. Olorinab has not yet been approved as a treatment in any country, but is currently in clinical trials for the treatment of IBS associated abdominal pain.
Phase 2 trial using Olorinab for IBS currently underway
A phase 2 clinical trial, known as the ‘CAPTIVATE’ trial is currently recruiting participants to evaluate the effectiveness and safety of Olorinab treatment. The treatment consists of 12-weeks Olorinab, three times per day, in patients who have IBS associated abdominal pain. The study will assess the ability of the drug to improve abdominal pain, and aims to enrol approximately 240 patients across the United States.
The commencement of this trial is a significant advancement in the treatment of IBS. “I am thrilled that the first subject has enrolled in Arena’s CAPTIVATE trial, supporting the advancement of novel pain management options within the digestive disease field,” said Lin Chang, MD, Professor of Medicine at the Vatche and Tamar Manoukian Division of Digestive Diseases at the University of California, Los Angeles. “The majority of IBS patients describe their most problematic symptom as frequent abdominal pain, which often significantly impacts their quality of life. With limited pain management options available for GI disorders, there is a clear unmet medical need and an opportunity to improve the lives of patients.”
For more information, or to join the study, you can visit the website: https://myibspainstudy.com/
Written by Deborah Tallarigo, PhD
News release – PR Newswire. Available from: https://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-first-subject-dosed-in-captivate-phase-2-trial-evaluating-olorinab-in-abdominal-pain-associated-with-irritable-bowel-syndrome-300890720.html